Angiogenesis is a complex process that is vital to health but is also a driving factor behind a broad range of malignant, ischaemic, inflammatory, infectious and immune disorders. For optimal efficacy and safety, therapies aimed at preventing angiogenic-mediated disorders must differentiate between healthy and pathological angiogenesis or neovascularisation. Aganirsen is an antisense oligonucleotide that inhibits the insulin receptor substrate (IRS)-1 angiogenic pathway by targeting the IRS-1 messenger RNA. To date, studies of aganirsen have focused mainly on ocular disorders because of the ability to assess non-invasively the effect of the drug on neovascularisation and to address the unmet need for effective therapies in these blinding disorders. Aganirsen (GS-101) eye drops inhibit progressive corneal neovascularisation and appear to be well tolerated. The drug may offer an alternative and/or adjunct to intraocular anti-vascular endothelial cell growth factor (VEGF) agents, which are the current reference standards to prevent neovascularisation in retinal diseases. This is because it has a different and potentially complementary mechanism of action and can be administered topically. Antisense oligonucleotides targeting IRS-1 may present a valuable new approach to control pathological angiogenesis in the eye and elsewhere.
of the eye offer a unique opportunity to study neovascularisation and the impact of intervention in the living organ.
Ocular neovascularisation can lead to irreversible visual impairment, whether by causing permanent harmful changes to the neuronal architecture of the retina or by making the cornea opaque. 8, 9 There is a universally recognised need for effective therapies in eye conditions involving neovascularisation. 10 For example, in the neovascular ('wet') form of age-related macular degeneration (AMD), which accounts for 80-90 % of severe vision loss in wet AMD 11 and affects up to 4.5 million people worldwide, 12 choroidal neovascularisation (CNV) leads to leakage of fluid, protein and blood behind the retina, resulting in impaired central vision. While the aetiology of wet AMD is complex and multifactorial, CNV is a final common pathway that is directly responsible for sight loss and presents a highly relevant target for therapeutic intervention.
Approximately 8 % of all individuals with diabetes develop proliferative diabetic retinopathy (PDR). 13 As with AMD, angiogenesis-dependent PDR is a major public health problem owing to the growing incidence of diabetes and rapidly ageing populations. Thus, an effective treatment for neovascularisation will benefit thousands of PDR patients. Although rare (3.9 % of cases), secondary neovascular glaucoma (NVG) contributes disproportionately to blindness 14 and is the second most common cause for enucleations 15, 16 across all eye diseases. Today's therapeutic approaches are insufficient and there is a need for better treatments.
In comparison with other retinopathies, retinopathy of prematurity (ROP) affects a relatively small number of patients. 17 However, the need for effective therapeutic strategies is critical because it affects newborns and can result in lifelong blindness. In addition, the incidence is increasing alongside the increase in the overall survival of premature babies. 18 Finally, at the front of the eye, neovascularisation is the main risk factor for corneal graft rejection, both pre-and post-graft. [19] [20] [21] The incidence of rejection is about 15 % after the first year, increasing to around 45 % at five years. 22 Considering that more than 45,000 people in the US alone underwent a corneal transplant in 2011, 23 neovascularisation associated with corneal graft rejection (NV-CGR) can affect thousands of people worldwide. Therefore, an effective treatment to reduce neovascularisation is essential.
Anti-vascular Endothelial Growth Factors in the Treatment of Ocular Neovascularisation
Angiogenesis is a complex process controlled by numerous interacting molecules, organised as overlapping signalling pathways operating intra-and extra-cellularly. In theory, any of these interacting molecules Anti-VEGF therapy (e.g. the monoclonal antibody ranibizumab) can be effective in ocular conditions in which neovascularisation and vascular hyperpermeability leads to blindness, especially wet AMD, 24 macular oedema, PDR and NVG. 25 Despite the success of ranibizumab in treating retinal diseases, it has the drawback that repeated intravitreal injections are typically required every 1-3 months to maintain efficacy, with a cumulative risk of adverse events.
In addition, despite treatment with potent VEGF inhibitors, only 30-40 % of AMD patients gain three lines in visual acuity and roughly every sixth patient continues losing visual acuity and progresses to legal blindness. 26 Furthermore, because VEGF is involved in a wide variety of physiological processes, the long-term ocular and systemic safety of anti-VEGF agents may be of some concern; 27 angiogenesis is essential for life and long-term inhibition of neovascularisation may also interfere with healthy angiogenesis. 28 Consequently, new therapies are needed that either improve upon the therapeutic benefits of ranibizumab and/or eliminate the need for repeated intravitreal administration.
With this in mind, the development of a therapeutic strategy that clearly distinguishes between healthy and pathological angiogenesis may require other targets other than the VEGF pathway, and a different type of inhibition than direct interference with protein-protein interactions. One such target is insulin receptor substrate (IRS)-1, a molecule that is overexpressed in neovascularisation but that Ocular Neovascular Disorders does not appear to be necessary for healthy angiogenesis. 29 When the IRS-1 messenger RNA (a non-protein target) is deactivated, neovascularisation is inhibited, but physiological angiogenesis is unaffected. 30 Deactivation of the IRS-1 mRNA, and thus interference with the IRS-1 angiogenic pathway, can be achieved using an antisense oligonucleotide.
Potential of Antisense Oligonucleotides
Antisense oligonucleotides are short, single-stranded DNA polymers that can base-pair with a specific single-stranded mRNA sequence to create a DNA/RNA hybrid that is not amenable to translation, thus inhibiting gene expression. They do not interfere directly with proteins 
Aganirsen -One Way Forward
Aganirsen (GS-101), developed by Gene Signal, is an antisense oligonucleotide that targets the IRS-1 mRNA. The drug may offer a valuable alternative and/or adjunct to anti-VEGF agents as it can be applied topically, a much simpler mode of administration rather than intravitreal injection. Furthermore, development experience to date suggests that it may have a positive long-term safety profile, as aganirsen inhibits neovascularisation without appearing to interfere with existing signalling pathways associated with healthy angiogenesis. 30 The drug has important therapeutic potential, as the number of patients that might benefit is significant, based both on the number and the nature of pathologies where aganirsen may be applicable.
Trials using aganirsen have so far focused mainly on ocular disorders because of the ability to visually assess its effect on neovascularisation, but also because of the unmet need for effective therapies in these disorders. Data from preclinical and animal models have demonstrated that aganirsen inhibits the expression of IRS-1 29, 30 and significantly inhibits corneal neovascularisation 32 and lymphangiogenesis. 33 In non-human primate eyes, topical administration of aganirsen results in significant and near complete inhibition of laser-induced CNV lesions with the most pronounced neovascularisation compared with vehicle-treated eyes (see Figures 1 and 2 ).
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The most advanced clinical trials of aganirsen have been conducted in neovascularisaiton associated corenal graft rejection (NV-CGR). The phase II trial was the first randomised controlled trial (RCT) on topical inhibition of angiogenesis in the cornea. 34 When applied twice daily, aganirsen eye drops significantly inhibited progressive corneal neovascularisation (see Figure 3) and were well tolerated. The phase III trial is currently closing.
Phase II trials are also planned for wet AMD, NVG and PDR. Hence, treatment with aganirsen could potentially benefit thousands of patients with conditions that are dependent on neovascularisation. Source : Cursiefen, et al., 2009. 34 
Conclusions

